Dr. Xueguan Lu 陆雪官
Chief Physician
Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Radiation therapy and comprehensive treatment for head and neck tumors, including nasopharyngeal, oropharyngeal, hypopharyngeal, laryngeal cancers, and brain tumors.
Dr. Lu is a Chief Physician with a doctoral degree and serves as a doctoral supervisor. Dr. Lu is the Director of the Head and Neck Specialty at the Radiation Therapy Center. Clinical focus includes diagnosis, radiation therapy, and comprehensive treatment for head, neck, and brain tumors.
Professional roles
- Member, Chinese Medical Association
- Member, Head and Neck Expert Committee, Chinese Society of Clinical Oncology (CSCO)
- Member, Radiation Therapy Expert Committee, Chinese Society of Clinical Oncology (CSCO)
- Member, Hypopharyngeal Cancer Quality Control Center, National Cancer Center
Name order: in Chinese the family name comes first (Lu Xueguan). Papers usually list the name as Xueguan Lu or Lu X.
Selected publications
41 papers on PubMed matched by name and affiliation; 19 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cancers (Basel), 2026 (senior author): Integrating Pretreatment Circulating Tumor HPV DNA and Tumor Volume for Risk Stratification in HPV-Positive Oropharyngeal Squamous Cell Carcinoma. PubMed 42512263
- Clin Transl Radiat Oncol, 2026 (senior author): Validation of the 9th edition cTNM classification for HPV-positive oropharyngeal carcinoma in a non-endemic Chinese cohort. PubMed 42112247
- Front Oncol, 2026 (senior author): Subsite-specific benefit of induction chemoimmunotherapy in HPV-negative oropharyngeal squamous cell carcinoma. PubMed 42370167
- Eur J Cancer, 2024 (senior author): Liquid biopsy with plasma Epstein-Barr virus DNA characterizes biological relapse for the prediction of cancer recurrence in non-disseminated nasopharyngeal carcinoma. PubMed 39486162
- Oral Oncol, 2024 (senior author): MR radiomics unveils neoadjuvant chemo-responsiveness with insights into selective treatment de-intensification in HPV-positive oropharyngeal carcinoma. PubMed 39341091
- Int J Radiat Oncol Biol Phys, 2024 (senior author): In Reply to Topkan et al. PubMed 38851260
- Int J Radiat Oncol Biol Phys, 2024 (senior author): Selective Treatment Deintensification by Reducing Radiation Dose and Omitting Concurrent Chemotherapy Based on Response to Induction Chemotherapy in Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma: A Single-Arm, Phase 2 Trial (IChoice-01). PubMed 37574169
- Quant Imaging Med Surg, 2023 (senior author): Applying multisequence MRI radiomics of the primary tumor and lymph node to predict HPV-related p16 status in patients with oropharyngeal squamous cell carcinoma. PubMed 37064405
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion